Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present OWC Pharmaceutical Research Corp. (OTC: OWCP).

Full DD Report for OWCP

You must become a subscriber to view this report.


Recent News from (OTC: OWCP)

5 of Today's Biggest Marijuana Stock Losers - Monday, May 7th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Monday, May 7th including MYM Neutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) and more... Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) Shares of Isodiol International Inc. dropped 6.78% ...
Source: Daily Marijuana Observer
Date: May, 07 2018 17:12
OWC Pharmaceutical Research Corp Raises $5 Million in Preferred Stock Sale to Institutional Investor
RAMAT GAN , Israel , May 3, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the closing of the sale of $5 million of convertible preferred stoc...
Source: PR Newswire
Date: May, 03 2018 09:00
5 of Today's Biggest Marijuana Stock Losers - Tuesday, March 13th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Tuesday, March 13th including THC BioMed Intl Ltd. (CSE:THC) (OTC:THCBF) and more... Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) Shares of Global Hemp Group Inc. dropped 5.2308% today o...
Source: Daily Marijuana Observer
Date: March, 13 2018 17:17
5 of Today's Biggest Marijuana Stock Losers - Monday, March 12th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Monday, March 12th including THC BioMed Intl Ltd. (CSE:THC) (OTC:THCBF) and more... Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) Shares of Global Hemp Group Inc. dropped 7.14% today on l...
Source: Daily Marijuana Observer
Date: March, 12 2018 18:05
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
PETACH TIKVA, Israel , March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders. In t...
Source: PR Newswire
Date: March, 08 2018 10:31
OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer
RAMAT GAN, Israel, Feb. 20, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Oron ...
Source: PR Newswire
Date: February, 20 2018 08:30
OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference
PETACH TIKVA, Israel , January 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. [OWC Pharma](OTCQB: OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. ( http://WallStConference.com )      (Logo: http://mma.prnew...
Source: PR Newswire
Date: January, 08 2018 08:00
OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
PETACH TIKVA, Israel, Dec. 21, 2017 /PRNewswire/ -- In December 2017 , OWC Pharmaceutical Research Corp (OTCQB: OWCP) received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be s...
Source: PR Newswire
Date: December, 21 2017 08:00
5 of Today's Biggest Marijuana Stock Losers - Friday, November 10th
Out of over 200+ marijuana stocks , here are 5 of the biggest marijuana stock losers in trading on Friday, November 10th including MassRoots, Inc. (OTC:MSRT) and more... CannaRoyalty Corp. (CSE:CRZ) (OTC:CNNRF) Shares of  CannaRoyalty Corp. dropped 5.29% today on the OT...
Source: Daily Marijuana Observer
Date: November, 10 2017 19:12
5 of Today's Biggest Marijuana Stock Losers - Monday, October 30th
Out of over 200+ marijuana stocks , here are 5 of the biggest marijuana stock losers in trading on Monday, October 30th including OWC Pharmaceutical Research Corp. (OTC:OWCP) and more... 22nd Century Group, Inc. (NYSE:XXII) Shares of 22nd Century Group, Inc. dropped 4.82% t...
Source: Daily Marijuana Observer
Date: October, 30 2017 17:54

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.16550.170.17750.165218,919
2018-08-160.17990.170.17990.165331,937
2018-08-150.176250.17580.180.17412,734
2018-08-140.1610.1750.17950.155258,046
2018-08-130.16810.16980.180.1574317,161

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1755,989222,23125.1941Cover
2018-08-1672,008357,01220.1696Cover
2018-08-15200,843415,93448.2872Short
2018-08-14132,449258,04651.3277Short
2018-08-1389,544317,16128.2330Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OWCP.


About OWC Pharmaceutical Research Corp. (OTC: OWCP)

Logo for OWC Pharmaceutical Research Corp. (OTC: OWCP)

OWC Pharmaceutical Research Corp. is engaged in the business, through its wholly owned Israeli subsidiary, One Word Cannabis Ltd. OWC , of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of medical cannabis specifically designed for the treatment of several illnesses/medical conditions. Under the direction of Dr. Yehuda Baruch, our Director of Research and Regulatory Affairs and Chief Science Officer, the Company has recently filed a patent application with the United States Patent and Trademark Office for its active cannabinoid based topical cream. OWC has also entered into an agreement with Mediq Innovation Partners for marketing OWC s topical psoriasis cream in Germany. OWC has also progressed on using specific dosages of its Cannabaniod based products administered through soluble pills taken orally, with its initial focus on PTSD, multiple myeloma and topical treatment of burns in addition to psoriasis. Our business plan includes entering into collaborative ventures with major medical centers and highly regarded researchers in Israel and potentially other countries with the goal of developing novel therapeutic methods for the treatment of serious medical conditions with cannabis based therapies and are conducting pre clinical investigations and randomized, placebo controlled trials of cannabis based compounds and develop unique, condition specific products.

 

Contact Information

 

 

Current Management

  • Mordechai Bignitz / CEO, President
    • Mr. Bignitz has over years of experience in investment banking, specializing in all aspects of the planning, negotiation and execution of both domestic and international transactions. Over the same period, Mr. Bignitz has had extensive experience in the management of investments and financial systems, accounting and taxation. During the past five years, he has served as a director of the following public companies: Arad Investment amp Industrial Development Ltd since February , traded on the TelAviv Stock Exchange TASE Globe Exploration Limited Partnership since July , traded on the TASE Ellomay Capital Limited since , engaged in investments in energy and infrastructures and traded on the NASDAQ and TASE Israel Financial Levers Ltd, since , engaged in the real estate business and traded on the TASE Ablon Group Ltd from to , engaged in the real estate business and traded on the London Stock Exchange Leader Holdings amp Investments Ltd from to , an investment company traded on the TASE and Leader Capital Markets, fro to , an underwriter and brokerage firm traded on the TASE.
  • Alon Sinai / COO
    • Mr. Sinai, COO and Interim CEO of the Company s whollyowned Israeli subsidiary, One World Cannabis Ltd., is a retired LieutenantColonel from the Medical Corps of IDF , and completed the NATO School Oberammergau program NATO s premier individual training and education facility at the operational level . Most recently he served as Head of the Doctrine, Instruction and Training Department, where he was responsible for commanding and developing emergency medical facilities, writing professional doctrine and literature for the IDF Medical Corps and working with foreign militaries. Mr. Sinai is currently pursuing his Ph.D. in Health Systems Management at BenGurion University of the Negev, where he previously earned an MA in Health Systems Management and a B.EMS in Emergency Medicine.
  • Yossi Dagan / CFO
    • Mr. Dagan, age , is a CPA and was recently appointed as the Registrant s CFO. From to present, Mr. Dagan has served as CFO of Top Image Systems Ltd NASDAQ: TISA , a reporting company organized in Israel, that employs over employees in the US, Israel, Germany, UK, Singapore, Japan and Brazil. Prior to that, Mr. Dagan served as: i VP of Finance at Kenshoo, an Israeli based global SaaS company employing employees ii Corporate Controller at Imperva Inc. NYSE: IMPV , a leading provider of cyber security solutions in the cloud and on premises that protect businesscritical data and applications. Mr. Dagan was a manager at PriceWaterhouseCoopers. He holds a CPA and a BA in Accounting and Business from The College of Management. Mr. Dagan began his accounting career at PriceWaterhouseCoopers in Israel in , received his degree as a Certified Public Accountant in Israel in and received his Bachelor of Business degree with a major in accounting in from The College of Management, Rishon Le Zion, Israel.
  • Yehuda Baruch / Chief Med. Officer
    • Dr. Yehuda Baruch, Chief Science Officer and Director of Research and Regulatory Affairs One World Cannabis Ltd. Dr. Baruch served as Head of the Israeli Ministry of Health s Medical Marijuana Program from through , directing their efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. Dr. Baruch has extensive experience in researching medical cannabis, most notably for its effect on PTSD. From until , Dr. Baruch also served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel, prior to which, he was the director of Israel s Ministry of Health medical management division, and director general of Be er Yakov Mental Health Center. He has taught at BenGurion University of the Negev and Tel Aviv University s Sackler School of Medicine. Management Team As Colonel in IDF s Medical Corps, Dr. Baruch was the director of the Israeli field hospital to India following the earthquake and was the director of the joint USAIsrael Mental Health Team operation in Sri Lanka post tsunami. Dr. Barch was the director of the Health Administration Division in the Israel Ministry of Health for years from to and for the past years hes has been the director of Abarbanel Mental Health Center and lecturer at Ben Gurion and Bar Ilan Universities. Dr. Yehuda Baruch is MD and MHA both from Tel Aviv University.
  • Dr. Oron Yacoby Zeevi / Chief Scientific Officer
  • Richard Rubin / Counsel
    • Richard Rubin, , has been SEC compliance and reporting consultant to the Registrant since January and has provided similar services to a number of public companies for more that the past twenty years. From until July , Mr. Rubin served as CEO, CFO and Chairman of Peregrine Industries Inc. OTCQB: PGID . During the past five years, Mr. Rubin has been engaged in the business of providing corporate securities compliance services to public companies, specifically in connection with their reporting obligations under the Exchange Act.
  • Dr. Stanley Hirsch / Chairman
    • Dr. Hirsch has extensive executive and board level experience for more than the past years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M amp A activity together with multicultural management skills, having managed companies in Israel, Brazil, UK, China and the United States. From May to the present, Dr. Hirsch has served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd NASDAQ: FOMX , an Israelibased clinicalstage specialty pharmaceutical company in latestage clinical development and commercializing two proprietary products for the treatment of acne, rosacea and other skin conditions. Foamix collaborates with leading global pharmaceutical companies in the creation and commercialization of its advanced skin treatment products. From August to the present, Dr. Hirsch has served as Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc, which was listed on the AIMLondon Stock Exchange, prior to acquisition by Suzano Pulp and Paper of Brazil SUZB, BOVESPA, Sao Paulo in July . FuturaGene Limited is a world leader in the development of environmentally friendly solutions that improve and protect crop yields, engaged in the development and delivery of sustainable genetic solutions for global forestry, biopower, biofuels, and agricultural markets.
  • Mordechai Bignitz / Chairman
    • Mr. Bignitz has over years of experience in investment banking, specializing in all aspects of the planning, negotiation and execution of both domestic and international transactions. Over the same period, Mr. Bignitz has had extensive experience in the management of investments and financial systems, accounting and taxation. During the past five years, he has served as a director of the following public companies: Arad Investment amp Industrial Development Ltd since February , traded on the TelAviv Stock Exchange TASE Globe Exploration Limited Partnership since July , traded on the TASE Ellomay Capital Limited since , engaged in investments in energy and infrastructures and traded on the NASDAQ and TASE Israel Financial Levers Ltd, since , engaged in the real estate business and traded on the TASE Ablon Group Ltd from to , engaged in the real estate business and traded on the London Stock Exchange Leader Holdings amp Investments Ltd from to , an investment company traded on the TASE and Leader Capital Markets, fro to , an underwriter and brokerage firm traded on the TASE.
  • Hannah Feuer /

Current Share Structure

  • Market Cap: $39,894,905 - 03/09/2018
  • Authorized: 500,000,000 - 03/01/2018
  • Issue and Outstanding: 147,758,908 - 03/01/2018
  • Float: 118,240,011 - 06/30/2017

 


Recent Filings from (OTC: OWCP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 16 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 20 2017

 

 


Daily Technical Chart for (OTC: OWCP)

Daily Technical Chart for (OTC: OWCP)


Stay tuned for daily updates and more on (OTC: OWCP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: OWCP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OWCP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of OWCP and does not buy, sell, or trade any shares of OWCP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/